// Biotech and Pharma Therapeutics
Abbott, Dexcom could benefit from CGM use jump among Type 2 diabetes patients: report
The population could drive the next wave of demand for devices to track and control diabetes, Jefferies analysts predict, based on polling of roughly 50 endocrinologists and general practitioners.
Nuvectis Pharma Stock: Developing Precision Targeted Therapies In Oncology (NVCT)
Nuvectis Pharma is building a pipeline of anticancer therapies utilizing precision targeting. NVCT filed for an IPO of $30 million. Here is a full investment analysis.
Supernus expands its portfolio of Parkinson’s drugs with a $400M+ buyout
Supernus is marking its expansion into the Parkinson’s disease arena, striking a deal to buy out Adamas Pharmaceuticals in a deal worth more than $400 million. A year after swooping in on its first Parkinson’s acquisition, the two companies announced that they had reached an agreement for Supernus t…
The energy switch: Big Pharma harnesses sun, wind and water in quest for a low-carbon future
From sales teams hitting the road in hybrid armadas to wind farms powering factories to on-site solar panels and more, Big Pharmas like Amgen, Novartis, Novo Nordisk and AstraZeneca—plus contract manufacturers and rising biotechs—are paving the way for more sustainable power options.
// 4th Industrial Revolution
Amazon and Big Pharma Unite to Propel AI Innovation in Therapeutics | BioSpace
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
3D Printing Applications in the Fight Against Breast Cancer - 3Dnatives
In honor of October, which is Breast Cancer Awareness Month, we have listed some of the ways that 3D printing is used in the fight against breast cancer.
DreaMed Diabetes’ ‘digital endocrinologist’ AI expands to Type 2 diabetes with FDA green light
It’s a common difficulty in many medical specialties: there typically aren’t enough specialists to go around. DreaMed Diabetes hopes to relieve some of the strain with its artificial-intelligence-powered system aimed not at patients but at clinicians.
Are ‘robot massages’ the future of muscle repair?
Researchers used a robotic massage device to treat damaged muscles in mice. The intervention worked, and the scientists drilled down into the mechanisms.
// Business & Markets
Latest investments: Medtronic, AION Labs, Tredence & more | Medical Devices & Pharma | Healthcare Global
We round up the latest investments, acquisitions and launches in healthcare. Medtronic's latest performance report includes a commitment to fill 45% of its global management positions with women, and 30% of US management positions with ethnically diverse talent by 2026.
Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Anticipated to Grow Globally at a CAGR of 23.6% during 2021-26
The "Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market" is likely to grow at a CAGR of around 23.6% during the forecast period, i.e., 2021-26, says the author. The market growth primarily attributes to the rising demand for reducing the cost of novel drug discovery and their production.
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.Collaboration with...
Three New Nasdaq Tickers and MPM Capital Secures $850 Million to Impact Oncology | BioSpace
After weeks of slowing initial public offerings within the biopharma and life sciences industries, within the last 24 hours, three companies announced plans to list their stocks on the Nasdaq. Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
// Legal & Regulatory
Rheumatoid arthritis: Scientists investigate potential vaccine
A study in rats identifies a protein that may help design a vaccine against rheumatoid arthritis. More research is necessary, but the results are encouraging.
Federal judge rejects a government bid to delay Purdue Pharma’s bankruptcy settlement
Judge Colleen McMahon was expected to halt work on the controversial settlement that would give immunity from opioid lawsuits to the Sackler family. Instead she allowed work on the plan to go ahead.
EU considers reform of general pharma law
The European Commission has begun a public consultation on potential reforms to EU general pharmaceutical law.
Merck Asks FDA to Authorize Promising Covid-19 Pill
Earlier this week pharmaceutical company Merck announced it has submitted an application to the Food and Drug Administration (FDA) for emergency use of what could be the first-ever pill to treat Covid-19. Because the antiviral drug can be delivered in series of convenient and relatively inexpensive capsules, some experts say it could be a game-changer in the fight against the virus.
// Research & Development
Challenges to Scientific Expertise: Future Implications for Oncology
The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.
Pacira Adds Flexion’s Zilretta to Non-Opioid Pipeline in $427 Million Deal | BioSpace
Zilretta is the first treatment approved by the U.S. FDA for OA knee pain that uses extended-release microsphere technology.
Corium Receives March 11, 2022 PDUFA Date for New Drug Application for ADLARITY® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) set a Prescription Drug User Fee (PDUFA) target action date of March 11, 2022 for Cori…
Imfinzi™ improves liver cancer survival in Phase III trial
Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.
Eli Lilly says legislation to address drug prices would hurt its current, future operations
Indianapolis-based Eli Lilly is joining other pharmaceutical companies in arguing against legislation that aims to reduce drug costs.
EU Health: MEPs call for a future-proof EU pharmaceutical policy
MEPs call for national and EU measures to guarantee all patients have safe and timely access to essential and innovative medicines, ENVI. The Committee on the Environment, Public Health and Food Safety (ENVI) adopted on Tuesday, with 62 votes in favour, eight against and eight abstentions, its recom…
Kaiser Family Foundation: Public not buying pharma’s arguments over drug price reforms
A new poll finds that a large swath of the public aren’t buying the pharmaceutical industry’s arguments against giving Medicare drug price negotiation authority.
HEALTH CARE BRIEFING: Mental Health Coverage Flaw Fines Targeted | Bloomberg Government
Democrats want to beef up enforcement of rules meant to make it easier to access mental health services using insurance. Business groups say the move won’t work and is a ploy to pay for Democrats’ wide-reaching social spending agenda.